Table 2 Treatment and Outcome characteristics of uterine sarcoma patients stratified on the histological type (n = 40)
Characteristics | All patients (n = 40) | u-LMS (n = 16) | HGESS (n = 10) | LGESS (n = 8) | Other histologic subtypes (n = 6) | p-value |
|---|---|---|---|---|---|---|
Primary surgery type, n(%) | ||||||
TAH + BSO | 12 (30.0) | 6 (50.0) | 3 (25.0) | 2 (16.67) | 1 (8.33) | |
TAH + BSO + PLND | 15 (37.50) | 3 (20.0) | 5 (33.33) | 4 (26.67) | 3 (20.0) | 0.045 |
TAH + BS + ovarian conservation | 7 (17.50) | 6 (85.71) | 1 (14.29) | 0 (0.0) | 0 (0.0) | |
Myomectomy | 3 (7.50) | 1 (33.33) | 0 (0.0) | 2 (66.67) | 0 (0.0) | |
Surgery not done | 3 (7.50) | 0 (0.0) | 1 (33.33) | 0 (0.0) | 2 (66.67) | |
Residual disease after primary surgery, n(%) | ||||||
Present | 8 (21.62) | 6 (75.0) | 2 (25.0) | 0 (0.0) | 0 (0.0) | 0.128 |
Absent | 29 (78.38) | 10 (34.48) | 7 (24.14) | 8 (27.59) | 4 (13.79) | |
Adjuvant chemotherapy received, n(%) | ||||||
Yes | 24 (60.0) | 7 (29.17) | 6 (25.0) | 5 (20.83) | 6 (25.0) | 0.123 |
No | 16 (40.0) | 9 (56.25) | 4 (25.0) | 3 (18.75) | 0 (0.0) | |
Chemotherapeutic regimen, n(%) | ||||||
Ifosfamide | 1 (4.17) | 1 (100.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Doxorubicin | 2 (8.33) | 1 (50.0) | 0 (0.0) | 0 (0.0) | 1 (50.0) | 0.760 |
Doxorubicin + Ifosfamide | 5 (20.83) | 2 (40.00) | 2 (40.00) | 1 (20.0) | 0 (0.0) | |
Gemcitabine + Docetaxel | 16 (66.67) | 5 (31.25) | 6 (37.5) | 1 (6.25) | 4 (25.0) | |
Number of Cycles received n (%) | ||||||
3 | 5 (20.83) | 1 (20.0) | 2 (40.0) | 0 (0.0) | 2 (40.0) | |
4 | 13 (54.17) | 7 (53.85) | 3 (23.08) | 2 (15.38) | 1 (7.69) | |
6 | 6 (25.0) | 1 (16.67) | 3 (50.0) | 0 (0.0) | 2 (33.33) | 0.311 |
Adjuvant Radiation Therapy, n(%) | ||||||
Yes | 9 (22.50) | 4 (44.44) | 2 (22.22) | 2 (22.22) | 1 (11.11) | 0.971 |
No | 31 (77.50) | 12 (38.71) | 8 (25.81) | 6 (19.35) | 5 (16.13) | |
Hormonal therapy, n(%) | ||||||
Yes | 5 (12.50) | 0 (0.0) | 2 (40.0) | 3 (60.0) | 0 (0.0) | 0.042 |
No | 35 (87.50) | 16 (45.71) | 8 (22.86) | 5 (14.29) | 6 (17.14) | |
Recurrences, n(%) | ||||||
Yes | 18 (45.0) | 5 (27.78) | 4 (22.22) | 5 (27.78) | 4 (22.22) | 0.327 |
No | 22(55.0) | 11 (50.0) | 6 (27.27) | 3 (13.64) | 2 (9.09) | |
Follow-up, n(%) | ||||||
Alive with disease | 12(30.0) | 4 (33.33) | 2(16.67) | 5 (41.67) | 1 (8.33) | |
Alive with remission | 22 (55.0) | 11(50.0) | 6 (27.27) | 3 (13.64) | 2 (9.09) | 0.049 |
Died | 6 (15.0) | 1(16.67) | 2(33.33) | 0 (0.0) | 3 (50.0) | |